Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://eliemtx.comNext earnings report:
15 May 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 21 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
CLYM Latest News
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D.
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® and Spinraza®. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers.
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass.
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.
What type of business is Climb Bio?
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
What sector is Climb Bio in?
Climb Bio is in the Healthcare sector
What industry is Climb Bio in?
Climb Bio is in the Biotechnology industry
What country is Climb Bio from?
Climb Bio is headquartered in United States
What is Climb Bio website?
https://eliemtx.com
Is Climb Bio in the S&P 500?
No, Climb Bio is not included in the S&P 500 index
Is Climb Bio in the NASDAQ 100?
No, Climb Bio is not included in the NASDAQ 100 index
Is Climb Bio in the Dow Jones?
No, Climb Bio is not included in the Dow Jones index
When was Climb Bio the previous earnings report?
No data
When does Climb Bio earnings report?
The next expected earnings date for Climb Bio is 15 May 2025